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Abstract
Background: Pathway-oriented experimental and computational studies have led to a significant
accumulation of biological knowledge concerning three major types of biological pathway events:
molecular signaling events, gene regulation events, and metabolic reaction events. A pathway
consists of a series of molecular pathway events that link molecular entities such as proteins, genes,
and metabolites. There are approximately 300 biological pathway resources as of April 2009
according to the Pathguide database; however, these pathway databases generally have poor
coverage or poor quality, and are difficult to integrate, due to syntactic-level and semantic-level
data incompatibilities.
Results: We developed the Human Pathway Database (HPD) by integrating heterogeneous human
pathway data that are either curated at the NCI Pathway Interaction Database (PID), Reactome,
BioCarta, KEGG or indexed from the Protein Lounge Web sites. Integration of pathway data at
syntactic, semantic, and schematic levels was based on a unified pathway data model and data
warehousing-based integration techniques. HPD provides a comprehensive online view that
connects human proteins, genes, RNA transcripts, enzymes, signaling events, metabolic reaction
events, and gene regulatory events. At the time of this writing HPD includes 999 human pathways
and more than 59,341 human molecular entities. The HPD software provides both a user-friendly
Web interface for online use and a robust relational database backend for advanced pathway
querying. This pathway tool enables users to 1) search for human pathways from different
resources by simply entering genes/proteins involved in pathways or words appearing in pathway
names, 2) analyze pathway-protein association, 3) study pathway-pathway similarity, and 4) build
integrated pathway networks. We demonstrated the usage and characteristics of the new HPD
through three breast cancer case studies.
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Conclusion: HPD http://bio.informatics.iupui.edu/HPD is a new resource for searching, managing,
and studying human biological pathways. Users of HPD can search against large collections of
human biological pathways, compare related pathways and their molecular entity compositions, and
build high-quality, expanded-scope disease pathway models. The current HPD software can help
users address a wide range of pathway-related questions in human disease biology studies.
Background
The study of biological pathways has become a central
topic in molecular systems biology [1]. While the precise
definition of "biological pathway" is still debatable, most
researchers regard a biological pathway as a series of inter-
connected cellular events among biomolecular entities. A
biological pathway can be activated by extracellular stim-
uli and lead to persistent changes of the biochemical state
of cells. There are three major types of molecular pathway
events (or, events for brevity) that define biological path-
ways:
￿ Signal transduction events. Common in signalling
pathways  (e.g., Wnt signaling pathway [2]), these
events define the interactions among molecular enti-
ties during signal transduction cascades, i.e., how
external stimuli such as molecules in the cellular envi-
ronment are transduced into intracellular molecular
signals that are relayed among different cellular
organelles. Examples of signal transduction events in
signalling pathways are protein-protein interactions,
protein post-translational modifications, protein
translocations, and protein complex formations/dis-
sociations.
￿ Enzymatic reaction events. Common in metabolic
pathways (e.g., glycolysis pathway), these events define
chemical reactions that metabolites (as either sub-
strates or products) and catalytic enzymes are involved
in. Examples of enzymatic reaction events are cata-
bolic reactions (breaking down of larger molecules to
produce energy) and anabolic reactions (synthesis of
cellular components from smaller molecules).
￿ Genetic regulation events. Common in genetic regu-
latory pathways (e.g., usually abbreviated as regulatory
pathways), these events define the dependent relation-
ships between regulatory entities, e.g., a transcription
factor that binds to specific DNA binding motifs, and
target entities, and a gene whose transcription is being
regulated by a transcription factor. In addition to gene
regulation events, regulatory pathways may also
include sRNA and sRNA target gene regulation.
Collecting and modeling biological pathways are critical
for interpreting "Omics" data [3]. For example, pathway
knowledge has been used to identify new functional mod-
ules from gene expression profiles [4,5] and relate gene
mutations to one another in polygenic diseases such as
breast cancer [6]. The development of biological pathways
can also help build disease biology models, from which
new hypotheses of targeted drugs and robust biomarkers
may be developed. For example, molecular entities in
FGFR1/PI3K/AKT signaling pathways, the Akt/PKB path-
way, the Met pathway, and the Wnt signaling pathway
have all been extensively investigated as potential cancer
drug targets [7-10]. Novel drug discovery strategies to
screen small molecules based on an entire pathway
instead of particular protein targets can also be developed
by designing global disease-related pathway inhibitors
[11]. Pathway studies have also shown promise in molec-
ular diagnostic applications, e.g., identifying efficacy and
toxicity biomarkers [12], and building new multi-marker
panels to improve prediction of disease prognosis and
development of treatment plans [13]. Ongoing efforts to
represent, develop, and apply pathway models will be cru-
cial for future genome medicine and personalized medi-
cine applications [14,15].
While there are approximately 300 biological pathway-
related online resources reported by Pathguide http://
www.pathguide.org/today, these resources have been
developed with variable degrees of data coverage, quality,
and utility [1]. Examples of high-quality biological path-
way database resources are: SPAD [16], CST [17], STKE
[18] and COPE [19] for signaling pathways; TRANSFAC
[20] for regulatory pathways; and KEGG [21], WIT [22],
ExPASy [23], UM-BBD [24] and HumanCyc [25] for met-
abolic pathways. In addition, new databases such as
HPRD [26], HAPPI [27], and STRING [28] have been
developed to provide available high-throughput protein-
protein interaction data to help fill gaps in rapidly grow-
ing molecular signaling pathway data. Recent efforts to
expand biological pathway coverage beyond a single path-
way event type have also been reported, e.g., NCI-PID
[29], Reactome [30], BioCarta [31], Pathway Commons
[32], Panther [33], Protein Lounge [34] and WikiPath-
ways [35]. However, by comparing the coverage of high-
quality protein-protein interactions from the HAPPI data-
base [27] with annotated human pathways documented
from the Reactome database, for example, it is not diffi-
cult to conclude that current coverage of known human
biological pathway events is 1–2 orders of magnitude
smaller than the theoretical maximum that can be definedBMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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by all known reliable human protein-protein interactions.
Therefore, many pathway biology studies begin by
expanding biological pathway data coverage and building
high-quality integrative pathway models.
The most reliable approach to expanding human pathway
data coverage without sacrificing data quality continues to
be database integration. While there are several computa-
tional techniques that can help predict metabolic path-
ways [36], regulatory pathways [37,38], and signaling
pathways [39], they all have limited applicability and are
thus beyond the scope of this work. However, integrating
biological pathway from different data sources has been
challenging, due to the heterogeneity in pathway data for-
mats, representation schemes, and retrieval methods. For
example, at the syntactic level, while many pathway data-
bases such as the NCI-PID [29], Reactome [30], and
KEGG [21] provide both molecular component and
molecular interaction data as XML documents, Protein
Lounge [34] and BioCarta [31] provide pathway details
(including molecular entities and pathway events) only in
TXT file and embedded pathway diagrams. Pathway
ontology standards such as PSI-MI [40] or BioPAX [41] or
GPML [42] can help resolve syntactic level data heteroge-
neity; however, these standards are relatively new and are
available only in a few recent systems such as cPATH [43],
NCI-PID [29], Reactome [30] and WikiPathways [35]. At
the semantic  level, incompatible pathway names, event
representations, and molecular entity identifiers also
poses challenges in querying pathway information across
pathway data sources, particularly those with comple-
mentary information. Pathway names from different
pathway data sources for the same pathway often differ
slightly and therefore are poor choices as identifiers. Iden-
tifying pathways directly using pathway molecular entities
can also be problematic, because the ensemble of molec-
ular entities referring to the same pathway may vary
among different annotation sources. Pathway molecular
entities may be referred to with any public sequence iden-
tifier, which includes RefSeq ID, HGNC symbol, GenBank
accession, SwissProt ID, UniProt name, KEGG ID, or IPI
number. Furthermore, different databases may choose to
provide available pathway information at different levels
of molecular detail, e.g., with protein post-translational
modification status, protein complex association status,
or cellular location information. In summary, pathway
data incompatibility at both the syntactic and semantic
levels has inhibited the growth of high-quality integrative
pathway data sources.
In this work, we describe the development of a new online
integrated pathway database resource, the Human Path-
way Database (HPD). HPD is an ongoing pathway data
warehousing project, in which we integrate all three types
of human pathway data and compile additional detailed
information on pathway genes, proteins, metabolites,
protein complexes, and pathway events. The concept of
developing an organism-specific integrated pathway data-
base resource is not unique, e.g., MAtDB [44] for manag-
ing all biological pathways for Arabidopsis and FlyMine
[45] for managing both functional genomics and pathway
data for Drosophila. Applying semantic-level data integra-
tion techniques, we collect, represent, and manage
human-specific pathway data in HPD based on informa-
tion from NCI-PID, Protein Lounge, KEGG, BioCarta, and
Reactome databases. HPD provides a comprehensive view
of current human biological pathway data, which consists
of a total of 999 pathways and 59,341 molecular entities.
Online HPD users may search the database for all relevant
pathway information related to query protein(s), identify
all pathways involving a query protein(s), and examine
details related to pathway components, molecular events,
and related pathways. Using three case studies, we show
how to take advantage of HPD online and backend data-
base querying capabilities to manage, query, and compare
different types of biological pathways for systems biology
studies. HPD is freely available online at http://bio.infor
matics.iupui.edu/HPD.
Results
Database content statistics
By integrating human biological pathway data from five
major curated sources, we have developed HPD, a human
pathway data warehouse. As of the current release, HPD
contained a total of 999 human pathways that cover all
three major types of pathway events. These pathways
cover 59,341 molecular entities and 16,271 pathway
events. As of April 2009, HPD contains the highest path-
way data coverage among all human biological pathway
databases publically available. Since HPD does not con-
tain new pathways derived computationally, the quality
of the database remains the same as that of each pathways
curated from their respective source databases. A compar-
ison of human pathways in HPD against several common
human pathway data sources is shown in Table 1. Top 100
pathways, genes/proteins and compounds are listed in the
additional file 1.
Scale distributions of integrated HPD pathways
Pathway scale can reflect the integrality of information
needed for a biological topic. Here, we define pathway
scale as the number of entities (nodes, including gene,
protein, complex and metabolite) or events (edges,
including interaction, reaction and regulation) involved
in a pathway. We performed a statistical analysis on Path-
way Scale Distribution (PSD) in the whole HPD, shown in
Figure 1, from which we can see that the PSD defined by
entity in Figure 1a is almost the same as the PSD defined
by event in Figure 1b. This result indicates that the ratio of
entity (node) number and event (edge) number in HPDBMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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pathways is almost fixed, which implies that the quality of
HPD is consistent. We can also find that the PSD defined
by gene/protein in Figure 1a is much closer to the PSD
defined by entity or event than the PSD defined by metab-
olite, interaction, reaction and regulation, which suggest
that using gene/protein number can represent pathway
scale more precisely. This is the most important evidence
not only for the implemental definition of pathway scale,
but also for the definition of pathway-pathway similarity,
both of which can be defined by the number of the Uni-
prot IDs mapped from genes or proteins in a pathway.
We can also notice that, since entities in a pathway here
also include protein complexes, each of which will only
count as one entity, the PSD defined by that entity is a lit-
tle bit lower than the PSD defined by gene/protein in Fig-
ure 1a. Both of the results in Figure 1a and 2b suggest that
the integration process of HPD is successful by consider-
ing pathway scales, but either small pathways or large
pathways may still be under-represented in the whole
HPD.
General online features
In Figure 2, we show the user interfaces of the Web-based
online version of HPD. It supports both standard and cus-
tomized user search options that allow them to specify a
list of genes/proteins or keywords as the query input.
Upon executing the queries, HPD can retrieve a list of
Table 1: A comparison of human pathways in HPD against several common pathway data sources.
BioCarta1 HumanCyc2 KEGG3 Reactome4 PID5 Protein 
Lounge6
HPD
Quality Scope of 
Content
Metabolic and 
signaling 
pathways
Metabolic 
Pathways
Metabolic, 
Regulatory, 
signaling, 
disease and 
drug 
pathways
Metabolic, 
signaling and 
regulatory 
pathways
Signaling and 
regulatory 
pathways
Metabolic, 
signaling and 
regulatory 
pathways
Metabolic, 
signaling and 
regulatory 
pathways
Curation 
Type
Manual Manual and 
Computation
al Prediction
Manual Manual Manual Manual Integrated 
from Manually 
curated 
database
Coverage Human 
Pathways
354 327 205 960 87 427 999
Events > 3000 > 1500 4149 3203 5232 NA 16271
Functionalit
y
Related 
Pathways
N oN oY e sN oN oN oY e s
Multiple 
Protein 
Search
No No No No Yes No Yes
Pathway-
Protein 
Association 
Table
No No No No No No Yes
Pathway-
Pathway 
Similarity 
Network
No No No No No No Yes
1 Data from http://www.biocarta.com (as of April 2009)
2Data from http://humancyc.org/ (as of October 2008)
3Data from http://www.genome.jp/kegg/ (as of March 2009)
4Data from http://www.reactome.org (as of April 2009)
5Data from http://pid.nci.nih.gov/ (as of April 2009)
6Data from http://www.proteinlounge.com (Commercial Version, as of April 2009)
** The count of HPD pathways has 39 pathways more than reactome since HPD utilizes 2004 Reactome (version 22 release). The next version 
would include the recent version from ReactomeBMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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related human pathways in an HTML table, with which
users can further explore pathway details by clicking the
hyperlink on a pathway ID in the table. In the pathway
detail HTML table that pops up, all listings of molecular
entities, events, related pathways, and reference resources
of a specific pathway are shown. Users can also directly
interact with advanced HPD features; by selecting the
pathway-protein association matrix applet (See Figure 3
for an example) and the pathway-pathway similarity
matrix applet (See Figure 4 as an example) Comprehen-
sive hyperlinks were built so that users can search for new
pathways based on visual analysis performed on the
applets. User queried pathway data stored in HPD can
also be downloaded as flat files without restriction to Aca-
demic users.
Case studies
To demonstrate the capabilities of HPD, we show three
case studies of increasing complexity and biological sig-
nificance to demonstrate how HPD could be used to solve
real-world biological pathway problems.
Case study 1: searching for biological pathways and their 
components based on a single query protein
Using the standard query box provided at the HPD home
page, we can search HPD for all biological pathways
involving  BRCA1_HUMAN  (a major protein involved
with breast cancer susceptibility). HPD returns a list of the
top 20 BRCA1-related pathways, which are ordered by
decreasing number of proteins that each pathway shares
among all pathway pairs from retrieved pathways. The
better the rank a retrieved pathway has, the more related
it should be to both the query protein BRCA1 and all
BRCA1-relevant pathways. In this list, highly-ranked path-
ways such as "Molecular Mechanisms of Cancer", "P53
Signaling", "DNA Repair Mechanism", and "BRCA1 path-
way" are all well characterized signaling pathways in
breast cancer. All pathways are hyperlinked to their own
detailed pathway information pages, which include
molecular entities (proteins, complexes and metabolites),
related pathways, events, and external pathway images
and reference articles. (See Figure 2 for details).
The Web page with the list of pathways related to BRCA1
also contains links to download data. Four types of data,
pathway list, pathway-protein association matrix, and
pathway-pathway similarity scores are downloadable as
flat files.
Note that the pathway-protein association matrix con-
tains proteins that are involved in the top 20 pathways
retrieved based on the single protein query, sorted accord-
ing to their descending maximal pathway involvement by
activity count. BRCA1 related proteins are retrieved by
pathway, with each of the proteins covered by at least two
of the 20 pathways. A close examination reveals that many
breast cancer susceptibility genes including BRCA1,
BRCA2, P53, PCNA [46], FOXA1 [47] and STK6 [48] from
recent individual studies and breast cancer biomarker
genes such as ERBB2, FGFR2, M3K1, and PTEN [49,50],
have all been found in this list.
Particularly noteworthy is the Applet in the HPD Web
page that shows all the query-related biological pathways
with involved proteins in a heat map. In Figure 3, BRCA1
related pathways and involved proteins are sorted and
used as two separate dimensions of the matrix. Mousing
over a color-filled cell invokes an applet tooltip message,
which shows the pathway and protein names.
HPD users can also visualize the pathway-pathway simi-
larity matrix (Figure 4) which shows the similarity score
among the BRCA1 related pathways. The pathway-path-
way similarity matrix allows users to visualize a cluster of
similar pathway pairs as a 2-D interactive heat map. This
heat map allows users to right click on any cell (shown in
Figure 4) to compare pathway pair on the heat map
Pathway scale distributions for HPD molecular entity data  and molecular event data Figure 1
Pathway scale distributions for HPD molecular entity 
data and molecular event data. A pathway scale refers 
to the number of molecular entities or molecular events 
involved in a given pathway. The frequency on the y-axis 
refers to the count of all pathways falling in the category of a 
particular pathway scale size on the x-axis. (a) Distributions 
of pathway scale by counting molecular entities. (b) Distribu-
tions of pathway scale by counting molecular events.BMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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(future versions will include multiple pathway selection)
by looking at the pathway-protein association matrix. This
facilitates better understanding for deriving novel path-
ways most similar to BRCA1 related pathways.
Case study 2: developing pathway-pathway similarity 
networks from heterogeneous data sources
Using the advanced HPD search function online, a user
can specify multiple proteins as the query input to obtain
a list of most relevant pathways related to the query pro-
tein set. For example, if the user enters "BRCA1_HUMAN,
FOXA1_HUMAN, STK6_HUMAN" as query inputs, a sig-
nificant number of pathways (Table 2) related to any of
the query protein inputs will be returned. To ensure
retrieved pathways are relevant to the query protein inputs
and to avoid overly restrictive filtering of related pathways
(e.g., requiring all pathways retrieved to contain all pro-
teins in the input query would be too restrictive), we can
use the concept of pathway similarity (see Methods sec-
tion for details) and apply a minimal pathway similarity
An overview core functionality of the online HPD software Figure 2
An overview core functionality of the online HPD software. (a) The HPD home page showing a query protein input 
box (supports multiple protein search using either gene names or UniProt identifiers). (b) A Web page containing the list of 
pathways retrieved as a result of a query protein input. Links to obtain pathway-pathway similarity matrix and pathway-protein 
association matrix and to download query-retrieved pathways were also shown on the Web page. (c) An advanced search page 
in which users may search pathways using gene name(s), with any term that appears within pathway names or with a list of one 
or more HPD Pathway IDs. This search retrieves a page similar to in (b). (d) A hyperlinked Web page showing pathway 
detailed information on molecular entities (Proteins, Complexes and Compounds) within the query pathway. (e) A hyperlinked 
Web page showing detailed pathway information on pathways similar to the query pathway. (f) A hyperlinked Web page show-
ing detailed pathway information on molecular events (Interaction/Reaction/Regulation) within the query pathway. (g) A hyper-
linked Web page showing pathway image link and reference articles.BMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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threshold {Si, j ≥ 0.2, and |Pi ∩ Pj| > 2}, i = 1...N, j = 1...N.
The threshold indicates at least 20% minimal shared
molecular entities with no fewer than 2 shared entities
between two pathways. After applying this filter, 25 path-
ways and 39 pathway pairs are retrieved.
In Figure 5, we show a visual display of the pathway-path-
way similarity network, using pathway similarity scores
retrieved from HPD using ProteoLens [51]. In order to gen-
erate a comprehensive perspective of breast cancer path-
ways seeded with the three initial query proteins, all five
types of data sources have been used. This observation
strengthens the claim for the necessity of integrating path-
ways from heterogeneous sources. HPD pathways in this
case study provide a good meta-model that connects our
fragmented pathway knowledge together in pathway-
pathway similarity networks. This global perspective, sup-
ported by integration of otherwise incompatible pathways
from different sources, enhances the chance of exposing
novel insights in the search for disease drug targets and
biomarkers.
In Figure 6, we show a comparison of using the "Multiple
Protein Search" feature among three databases: HPD,
KEGG, and Panther. Three gene names BRCA1, FOXA1,
and AURKA were used to build a common query gene set.
The KEGG Genes database was manually searched and
only one KEGG Pathway was found, using the "Search
object in Pathways" functionality of KEGG (actual corre-
sponding KEGG gene ID entered: hsa:672, hsa:3169, and
hsa:6790). Panther had a "Batch ID search" which
accepted the three gene symbols and retrieved only four
unique pathways. HPD not only retrieved more pathways
(n = 25), but also supported multiple identifier types as
inputs, e.g., UniProt names.
Case study 3: developing integrated pathway models from 
heterogeneous sources
While pathway-pathway similarity networks are useful for
generating global perspectives on the relationships
between pathways, the next case study demonstrates how
to connect different types of biological pathways within
HPD to form integrated pathway networks. Since pathway
data managed at HPD is integrated at the schematic level,
"deep integration" and "deep integrative analysis" are
possible. We will use two breast cancer-related proteins,
BRCA1_HUMAN and FOXA1_HUMAN, as an example.
According to the HPD data model (See additional file 2
A BRCA1-retrieved HPD pathway-pathway similarity matrix Figure 4
A BRCA1-retrieved HPD pathway-pathway similar-
ity matrix. This is an interactive heat map containing simi-
larity scores among the pathways involving query protein(s) 
or gene name(s). The tooltip shows the two pathway IDs and 
names corresponding to the particular cell pointed to along 
with their similarity score. A right click context menu shows 
the links (HPD_644 and HPD_340) to a Web page containing 
pathway information (as shown in Figure 2d). The "Compare 
HPD_644 against HPD_340" option will redirect to a page 
with a pathway-protein matrix showing proteins shared by 
these two pathways. The legend above the map indicates the 
range of similarity score (0 to 1).
A BRCA1-retrieved HPD pathway-protein association matrix Figure 3
A BRCA1-retrieved HPD pathway-protein associa-
tion matrix. The matrix shows few HPD pathways involving 
the query protein BRCA1 (on the y-axis) against pathway 
molecular components (on the x-axis). A red cell in the 
matrix indicate that the molecular entity is present in the 
pathway, whereas a white cell in the matrix indicate that the 
molecular entity is absent from the pathway. Only few HPD 
pathways are shown. These BRCA1-retrieved pathways are 
sorted by their shared protein counts among all pairwise 
pathway comparisons in these pathways.BMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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for details), the table Connect_mol_updated contains map-
pings among pathways, interactions, and molecules. To
search for all related pathways containing the above two
proteins within the HPD data warehouse, we can execute
the following SQL query:
SELECT pathway_name,mol_in, Mol_In_updated,
name_in, Mol_out,
Mol_Out_updated, name_out, interaction_type,
SYS_CONNECT_BY_PATH(Mol_In, '/') "Path"
FROM connect_mol_updated
START WITH name_in = 'BRCA1_HUMAN'
CONNECT BY nocycle PRIOR
Mol_Out_updated=Mol_In_updated
and level < 3
INTERSECT
SELECT pathway_name,mol_in, Mol_In_updated,
name_in, Mol_out,
Mol_Out_updated, name_out, interaction_type,
SYS_CONNECT_BY_PATH(Mol_In, '/') "Path"
FROM connect_mol_updated
START WITH name_in = 'FOXA1_HUMAN'
CONNECT BY nocycle PRIOR
Mol_Out_updated=Mol_In_updated
and level < 3;
We organize the results and present our final pathway
analysis results in Figure 7, which shows many relation-
ships not found in individual fragmented biological path-
ways separately. The FOXA1 transcription factor network
contains 9-cis-Retinoic acid which regulates FOXA1
(Hepatocyte nuclear factor 3-alpha) [52]; it also contains
BRCA1 (Breast cancer type 1 susceptibility protein) and
CYP2C18 (Cytochrome P450 2C18), which is positively
regulated by FOXA1 [53]. Arachidonic acid metabolism
from KEGG PATHWAY involves arachidonic acid, which
can be catalyzed by CYP2C18  [54] to produce 14,15-
epoxy-5,8,11-eicosatrienoic acid. This intermediate prod-
uct can be further catalyzed by EPHX2 (Epoxide hydrolase
2) to produce 14,15-dihydroxyeicosatrienoic acid [55]. In
BioCarta, ATM signaling pathway involves BRCA1, which
positively regulates RAD51 which regulates DNA Repair
[56]. The "Presynaptic phase of homologous DNA pairing
and the strand exchange" pathway of Reactome contains
BRCA2, which binds with RAD51  to form the
RAD51:BRCA2  complex [57]. Human protein-protein
interactions data could also be retrieved and show that
EPHX2 interacts with NSDHL (Sterol-4-alpha-carboxylate
3-dehydrogenase, decarboxylating). Phosphatidylinosi-
tol-3,4,5-triphosphate (PIP3), a lipid molecule generated
by the action of phosphoinositide-3-kinase (PI3K), can be
induced by a variety of stimuli. PIP3 is thought to be the
major physiological substrate for PTEN, a phosphatase
Table 2: A list of HPD pathways retrieved by the query BRCA1.
Pathway_ID Pathway_Name Source_Name Shared_Proteins
HPD_786 Molecular Mechanisms of Cancer Protein Lounge 264
HPD_953 JAK/STAT Pathway Protein Lounge 239
HPD_1182 p53 Signaling Protein Lounge 76
HPD_1567 DNA Repair Mechanism Protein Lounge 69
HPD_336 Chks in Checkpoint Regulation Protein Lounge 52
HPD_596 BRCA1 Pathway Protein Lounge 44
HPD_1058 Aurora A signaling NCI-Nature Curated 43
HPD_1070 BARD1 signaling events NCI-Nature Curated 40
HPD_788 ATM Pathway Protein Lounge 33
HPD_644 role of brca1 brca2 and atr in cancer susceptibility BioCarta 27
HPD_988 Ubiquitin mediated proteolysis KEGG 25
HPD_12 cell cycle: g2/m checkpoint BioCarta 23
HPD_628 atm signaling pathway BioCarta 20
HPD_340 GADD45 Pathway Protein Lounge 19
HPD_752 Fanconi's Anaemia Pathway Protein Lounge 17
HPD_548 DNA Damage Induced 14-3-3Sigma Signaling Protein Lounge 14
HPD_212 brca1 dependent ub ligase activity BioCarta 11
HPD_1261 FOXA1 transcription factor network NCI-Nature Curated 10
HPD_707 Recruitment of repair and signaling proteins to double-strand breaks Reactome 9
HPD_276 ATM mediated phosphorylation of repair proteins Reactome 5BMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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that can dephosphorylate many phosphatidyl inositides,
which has been implicated in tumorigenesis [58]. Activa-
tion of protein kinase B (PKB)/Akt contribute to resistance
to antiproliferative signals and breast cancer progression
in part by impairing the nuclear import and action of p27
(CDKN) [59].
The integrated pathway model based on HPD pathways
can be used as an investigative tool for disease diagnostic
and therapeutic applications. For example, 9-cis-Retinoic
acid is recognized as a possible breast cancer biomarker
[60] and FOXA1 has gained increasing attention as a pos-
sible breast cancer therapeutic target [61]. The BRCA2-
RAD51 interaction is essential for DNA repairs and has
also been suggested as a novel target for anti-breast cancer
drugs [62]. In addition to breast cancer, links between
breast cancer and other diseases can be studied. For exam-
ple, increased risk of hereditary prostate cancer is known
to be a result of polymorphism in the CDKN1B (p27) gene
[63]. Epoxide hydrolase 2 has been characterized as a key
mediator molecule in hypertensive, cardiovascular,
inflammatory, pulmonary, and diabetic-related diseases
[64-66]. CHILD syndrome, an X-linked dominant trait
with lethality for male embryos, can also be traced to
mutations in NSDHL, a gene playing crucial roles in the
cholesterol biosynthetic pathway [67].
Through this case study, we have shown the significance
of integrating pathway information from different types
and data sources. The interconnected network analysis
offers researchers a rare opportunity to gain global per-
spectives on events previously perceived in isolation. This
"deep integrative analysis" opportunity cannot be readily
obtained by using multiple online pathway databases. For
example, NCI Nature Curated Pathway Interaction Data-
base has a 'Connected Molecules' functionality, which
may only be used to find molecular connections within
the same pathway data source. In all, the convenience of
building new integrative pathway models with the new
HPD may greatly facilitate new drug development and
biomarker discovery.
A breast cancer-specific pathway-pathway similarity network Figure 5
A breast cancer-specific pathway-pathway similarity network. In this pathway-pathway similarity network, 25 HPD 
pathways derived from different sources are shown. The color and shapes in the diagram were drawn to indicate original HPD 
pathway data sources, based on the shape/color legend shown in the upper left corner. The subnetwork pathways and host 
pathways are also indicated with directed cyan edges. Edges are labeled with the number (in red) of molecular entities shared 
by the connected pathways. The count of molecular entity overlap between each pair of related pathways is labeled as red-
colored numbers on the edge. Only pathway pairs with a similarity score and overlap above the threshold {Si, j ≥ 0.2, AND |Pi ∩ 
Pj| >2} are shown.BMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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Conclusion
We developed HPD as an integrated pathway database
system to manage, query, and analyze human biological
pathways. HPD integrates all three types of biological
pathways from five heterogeneous pathway database
sources at syntactic, semantic, and schematic levels, pri-
marily based on data warehousing techniques driven by a
unified pathway data model. Pathway molecules, interac-
tions, chemical reactions, and similar pathways can be
searched, displayed, and downloaded from a unified
online user interface. The current HPD software can help
users address a wide range of pathway-related questions in
human disease biology studies.
While the human Reactome is still far from complete, an
integrative pathway database such as HPD has the capa-
bility to help researchers establish a global perspective
necessary for understanding molecular mechanisms and
develop biomedical applications. We will further expand
the database to include pathways from HumanCyc [25],
Wikipathways [35], NetPath [68], Panther [33] and
TRANSFAC [20]. We also plan to integrate protein-protein
interaction data from HAPPI [27] with the aim of discov-
ering novel pathways when combined with HPD. Addi-
tional functions will also be provided such as pathway
reconstruction where users can select pathways and derive
a reconstructed pathway expanded with protein-protein
A comparison of HPD "Multiple Protein Search" feature with those in Panther and KEGG Figure 6
A comparison of HPD "Multiple Protein Search" feature with those in Panther and KEGG. The example shows 
that different pathway databases retrieved different numbers of pathways. Three genes (AURKA, BRCA1, and FOXA1) were 
used to build this example. The KEGG database returned only one pathway in the result. Panther returned four pathways. 
HPD returned 25 pathways. The difference is primarily due to the use of "similar pathways" concept to allow retrieval of path-
ways that matched only partial gene/protein list.
4 Unique Pathways
Insulin/IGF pathway-protein kinase B signaling cascade->Forkhead
transcription factor
PI3 kinase pathway->FOXO
Interleukin signaling pathway->Forkhead in Rhabdomyosarcoma-like 
1
TGF-beta signaling pathway->Co-activators or corepressorsBMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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interaction data. With ongoing efforts, HPD can become a
useful resource, linking proteins, genes, RNAs, signaling
reactions, and gene regulatory events for systems biology
applications.
Methods
Pathway data sources
We show an overview of the data integration process in
Figure 8. Pathway data in HPD were collected or indexed
from five different sources, i.e., NCI-Nature Curated data
[29], BioCarta [31], Protein Lounge [34], Reactome [30]
and KEGG [21]. The NCI-Nature Curated, Reactome and
BioCarta data sets were all downloaded from Nature path-
way interaction database Website and kept updated as of
April 2009 release of the production HPD Website. In par-
ticular, the NCI-Nature Curated pathways are curated by
Nature Publishing Group editors based on known biomo-
lecular interactions and key cellular processes of signal-
ing/regulatory pathways. The Reactome database was
downloaded in December 2007 (Release version 22).
Pathway molecules from both NCI-Nature and Reactome
were identified by their UniProt identifiers and annotated
with post-translational modification information. Path-
way molecules from BioCarta were identified by Entrez
Gene IDs without post-translational modification annota-
tions. In all three data sets, each pathway was represented
as a series of events, each of which consists of molecules
in one of the following four roles: input molecule, output
molecule, agent, and inhibitor. Content from the Protein
Lounge was indexed by a web crawler accessing a publicly
available Web site. The crawled content was verified with
that provided as a site license to the authors and other
users at Indiana University Simon Cancer Center. Since
Protein Lounge is a commercial database that contains
curated signaling, transduction, and metabolic pathways,
we chose to index instead of integrate the full content into
the data warehouse, which only indexed pathway-involv-
ing protein IDs and references to pathway diagram draw-
ings. Original pathway molecules derived from Protein
Lounge were identified by RefSeq ID or GI accession num-
bers. KEGG contains all known metabolic pathways and a
small number of regulatory pathways and transport mech-
anisms. The KEGG PATHWAY database contains graphi-
cal representations of pathways and lists of enzymes and
reactions within the pathways. All specific pathway maps
and overviews were manually drawn and contained links
to additional information on pathway compounds,
enzymes and genes. Pathway molecules from KEGG are
identified by E.C. Numbers which are mapped to KEGG
Gene IDs and then to UniProt IDs. The total count of ini-
tial pathways, proteins, compounds, protein complexes,
and pathway interactions are shown in Figure 8.
Pathway data integration
We developed a model-driven approach for syntactic,
semantic, and schematic level integrations of heterogene-
ous pathway data. Since pathway data were collected in a
variety of formats, Python XML/HTML data parsers were
developed to convert them into a common tab-delimited
textual format to ensure syntactic level data compatibility.
The semantic compatibility of the data was enforced by
cleaning up data attributes and data values to keep them
An overview of pathway data integration process Figure 8
An overview of pathway data integration process. The 
figure shows the whole process of pathway data integration 
and the basic statistics of pathway data sources. An integrated pathway model involving FOXA1 in breast  cancer Figure 7
An integrated pathway model involving FOXA1 in 
breast cancer. The figure shows how information from dif-
ferent pathway database sources are readily integrated, que-
ried, and analyzed together in HPD for FOXA1-related 
breast cancer signaling studies.BMC Bioinformatics 2009, 10(Suppl 11):S5 http://www.biomedcentral.com/1471-2105/10/S11/S5
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consistent, using a standard data extraction, transforma-
tion, and loading (ETL) process characteristics of data
warehousing-based data integration approaches. All pre-
processed data were parsed, cleaned, and loaded into data
warehouse staging tables before reaching their final data-
base table destinations. To maintain schematic data com-
patibilities, we model relationships among different
pathway concepts using an entity-relationship (ER) data
model (for more details on the data model, please refer to
the documentation on the HPD Website and additional
file 2). We further mapped all the involved proteins or
genes to their UniProt Name Identifiers [69] and metabo-
lites to their KEGG compound IDs before loading the
HPD pathway data into data warehouse tables defined by
the ER data model. All HPD molecular entities, events,
and pathways were assigned unique HPD-specific identi-
fiers.
Online HPD software design
The HPD database was developed as a data warehouse
application. The online version of HPD is a standard 3-tier
Web application, which consists of an Oracle 10 g data-
base at the backend database server layer, Apache/PHP
server scripts at the middleware application Web server
layer, and CSS-driven Web pages presented at the browser.
Pathway similarity measure
The pathway similarity measure can be defined as the
extent of overlaps, e.g., common number of genes/pro-
teins, shared between two different pathways. We define a
pathway-pathway similarity score Si, j based on equation
(2) [70]. Both overlap and similarity score values can be
downloaded from HPD Website.
Here,  N  denotes total number of pathways. Pi and  Pj
denote two different pathways, while |Pi| and |Pj| are the
numbers of molecules that can be mapped to UniProt ID
respectively in these two pathways. Their intersection Pi ∩
Pj denotes a common set of molecules that can be mapped
to the same UniProt ID, while their union Pi ∪ Pj is calcu-
lated as |Pi| + |Pj| - |Pi ∩ Pj|. Here α is a weight coefficient
among [0, 1], and we currently use α = 0.8 to count vary-
ing degree of contributions from calculations based both
on the overlap (left item SL) and the cover (right item SR).
We can also make special considerations for subnetwork
relationship (defined by the Nature Pathway Interaction
database at http://pid.nci.nih.gov/. For subnetwork rela-
tionship, we define Si, j = 1.01, if pathway Pi has a subnet-
work as Pj, and Si, j = -1.01 if pathway Pi is a subnetwork of
Pj.
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